PuraPly® AM Plus the Standard of Care to Standard of Care Alone for the Management of Stage II-IV Pressure Ulcers.

NATerminatedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 1, 2018

Primary Completion Date

September 15, 2021

Study Completion Date

September 15, 2021

Conditions
Chronic Pressure Ulcers
Interventions
DEVICE

PuraPly® Antimicrobial Wound Matrix

PuraPly® AM is a class II medical device, that has been 510(k) cleared by US Food and Drug Administration (FDA) (K051647) and is intended for the management of acute and chronic wound management across a variety of wound types, including partial- and full-thickness wounds, pressure ulcers, surgical wounds, trauma wounds, venous and diabetic ulcers.

OTHER

SOC for Pressure Ulcers

SOC group will receive institutional standard of care which includes, but is not limited to, debridement, negative pressure wound therapy (i.e. VAC), ensuring perfusion and oxygenation, evaluating nutritional status and addressing deficits, offloading, keeping the ulcer bed moist with appropriate cleansing at the time of each dressing change. Standard dressings may include hydrocolloids, alginates, transparent film, foam, moist gauze dressings. In addition, a non-toxic topical antiseptic, may be used per NPUAP Clinical Practice Guidelines (2014) for SOC group only, if colonization is suspected.

Trial Locations (2)

11402

Northwell Health, Lake Success

11501

NYU Winthrop Hospital, Mineola

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Organogenesis

INDUSTRY

NCT03502824 - PuraPly® AM Plus the Standard of Care to Standard of Care Alone for the Management of Stage II-IV Pressure Ulcers. | Biotech Hunter | Biotech Hunter